Corvus Pharmaceuticals, Inc. — Director's Dealing 2023

Dec 8, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2023-12-06

Reporting Person: Mitchell Edith P. (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-06	Stock Option (Right to Buy)	$1.64	A	15000	Acquired	2033-12-06	Common Stock (15000)	Direct

Footnotes

F1: The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.